Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **terminal D-alanyl-D-alanine** of peptidoglycan precursor is a specific dipeptide motif located at the end of the pentapeptide stem of the nascent peptidoglycan subunits in most bacteria[3][6][7][2]. These peptidoglycan precursors are critical intermediates in bacterial cell wall biosynthesis: they are transported to the outer face of the cytoplasmic membrane, where they are polymerized and cross-linked to form the rigid peptidoglycan mesh that protects bacterial cells from osmotic pressure and environmental stress[1][6][2]. The D-alanyl-D-alanine motif is the recognition site for both cell wall-assembling enzymes (penicillin-binding proteins, transpeptidases) and for glycopeptide antibiotics such as vancomycin, which bind tightly to it and thereby prevent proper formation and cross-linking of the peptidoglycan, leading to bacterial death[6][2]. Resistance to vancomycin is associated with mutations in bacteria that replace this motif, most commonly with D-alanyl-D-lactate, thus reducing antibiotic affinity[6]. This motif is not a protein or receptor, but a chemically well-defined bacterium-specific peptide structure, and is a validated therapeutic target for several clinically-important antibiotics.
Glycopeptide antibiotics (e.g., vancomycin) bind to the terminal D-alanyl-D-alanine motif of peptidoglycan precursors, inhibiting transglycosylation and transpeptidation required for cell wall cross-linking, and thereby blocking bacterial cell wall synthesis[6][3][2].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Terminal D-alanyl-D-alanine of peptidoglycan precursor.